StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

KPIs

Operating metrics that drive Merck's business · fiscal year ends Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Add to chartMetric
Q2 2026
2026-06-30
Q1 2026
2026-03-31
Q4 2025
2025-12-31
Q3 2025
2025-09-30
Q2 2025
2025-06-30
Q1 2025
2025-03-31
Q4 2024
2024-12-31
Q3 2024
2024-09-30
Q2 2024
2024-06-30
Q1 2024
2024-03-31
Q4 2023
2023-12-31
Q3 2023
2023-09-30
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide sales ($M)($M)5
7,9047,9068,3378,1427,9567,2057,8367,4297,2706,9476,6086,338
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — U.S. sales ($M)($M)1
4,6114,5994,8924,8794,7494,3084,8414,5004,4124,1193,9723,795
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — U.S. reported growth YoY (%)(%)
-3.0%1.0%8.0%8.0%5.0%22.0%19.0%14.0%18.0%18.0%14.0%
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — International sales ($M)($M)1
3,2933,3073,4453,2633,2072,8972,9962,9292,8582,8282,6362,543
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — International reported growth YoY (%)(%)
3.0%15.0%11.0%12.0%2.0%14.0%15.0%19.0%22.0%27.0%21.0%
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide reported growth YoY (%)(%)
-1.0%6.0%10.0%9.0%4.0%19.0%17.0%16.0%20.0%21.0%17.0%
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-2.0%5.0%8.0%9.0%21.0%21.0%24.0%22.0%17.0%
Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous, launched Q3 2025) — Worldwide sales ($M)($M)2
46312800
Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous, launched Q3 2025) — U.S. sales ($M)($M)
39510600
Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous, launched Q3 2025) — International sales ($M)($M)
682100
Welireg (belzutifan — HIF-2α inhibitor) — Worldwide sales ($M)($M)4
271199220196162137160139126857254
Welireg (belzutifan — HIF-2α inhibitor) — U.S. sales ($M)($M)1
214152181161138123146127116776851
Welireg (belzutifan — HIF-2α inhibitor) — U.S. reported growth YoY (%)(%)
55.0%24.0%27.0%19.0%59.0%114.0%148.0%138.0%89.0%
Welireg (belzutifan — HIF-2α inhibitor) — International sales ($M)($M)
574739352415141210743
Welireg (belzutifan — HIF-2α inhibitor) — Worldwide reported growth YoY (%)(%)
67.0%37.0%42.0%29.0%62.0%122.0%156.0%150.0%102.0%79.0%43.0%
Welireg (belzutifan — HIF-2α inhibitor) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
67.0%37.0%41.0%29.0%123.0%150.0%102.0%78.0%43.0%
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — Worldwide sales ($M)($M)4
365341389379370312365337317292315299
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — U.S. sales ($M)($M)1
167149180184174145177161153135168153
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — U.S. reported growth YoY (%)(%)
-4.0%1.0%14.0%14.0%7.0%5.0%5.0%6.0%-4.0%7.0%7.0%
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — International sales ($M)($M)1
198192209195195168187177165157147146
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — International reported growth YoY (%)(%)
2.0%12.0%11.0%19.0%7.0%28.0%21.0%-1.0%18.0%9.0%4.0%
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — Worldwide reported growth YoY (%)(%)
-1.0%7.0%12.0%17.0%7.0%16.0%13.0%2.0%6.0%8.0%5.0%
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-2.0%4.0%12.0%15.0%18.0%4.0%7.0%8.0%6.0%
Lenvima (lenvatinib — Eisai oncology alliance revenue) — Worldwide sales ($M)($M)4
283256272258265258255251249255226260
Lenvima (lenvatinib — Eisai oncology alliance revenue) — U.S. sales ($M)($M)1
194176191177183186182173177173181160
Lenvima (lenvatinib — Eisai oncology alliance revenue) — U.S. reported growth YoY (%)(%)
6.0%5.0%2.0%3.0%8.0%1.0%9.0%8.0%13.0%18.0%13.0%
Lenvima (lenvatinib — Eisai oncology alliance revenue) — International sales ($M)($M)1
9080808183727378738245100
Lenvima (lenvatinib — Eisai oncology alliance revenue) — International reported growth YoY (%)(%)
8.0%11.0%4.0%14.0%-12.0%63.0%-22.0%-7.0%3.0%-28.0%67.0%
Lenvima (lenvatinib — Eisai oncology alliance revenue) — Worldwide reported growth YoY (%)(%)
7.0%7.0%3.0%6.0%1.0%13.0%-3.0%3.0%10.0%5.0%29.0%
Lenvima (lenvatinib — Eisai oncology alliance revenue) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
6.0%6.0%2.0%5.0%14.0%4.0%10.0%5.0%30.0%
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — Worldwide sales ($M)($M)4
12214816413610711911010090717052
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — U.S. sales ($M)($M)1
9812813311188101888275586043
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — U.S. reported growth YoY (%)(%)
11.0%51.0%35.0%18.0%72.0%47.0%93.0%110.0%93.0%68.0%34.0%
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — International sales ($M)($M)1
252031251918221815121010
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — International reported growth YoY (%)(%)
31.0%37.0%40.0%24.0%47.0%124.0%83.0%36.0%74.0%42.0%
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — Worldwide reported growth YoY (%)(%)
15.0%48.0%36.0%19.0%68.0%58.0%91.0%92.0%66.0%69.0%35.0%
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
15.0%48.0%36.0%19.0%58.0%92.0%66.0%69.0%35.0%
Koselugo (selumetinib — AstraZeneca NF1 alliance revenue) — Worldwide ($M)($M)
01322711595563937382326
Total Vaccines Franchise — Worldwide sales ($M)($M)
01325797035955465927157452,9624,002
Gardasil / Gardasil 9 (HPV recombinant vaccine) — Worldwide sales ($M)($M)5
1,1691,0691,0311,7491,1261,3271,5502,3062,4782,2491,8712,585
Gardasil / Gardasil 9 (HPV recombinant vaccine) — U.S. sales ($M)($M)1
5424854061,1545455363801,020536488365838
Gardasil / Gardasil 9 (HPV recombinant vaccine) — U.S. reported growth YoY (%)(%)
-1.0%7.0%13.0%2.0%10.0%4.0%22.0%17.0%
Gardasil / Gardasil 9 (HPV recombinant vaccine) — International sales ($M)($M)1
6265856255955817901,1701,2851,9411,7611,5061,746
Gardasil / Gardasil 9 (HPV recombinant vaccine) — International reported growth YoY (%)(%)
8.0%-47.0%-54.0%-70.0%-55.0%-22.0%-26.0%13.0%
Gardasil / Gardasil 9 (HPV recombinant vaccine) — Worldwide reported growth YoY (%)(%)
4.0%-34.0%-24.0%-55.0%-41.0%-17.0%-11.0%1.0%14.0%
Gardasil / Gardasil 9 (HPV recombinant vaccine) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
3.0%-35.0%-25.0%-55.0%-18.0%4.0%17.0%
Gardasil / Gardasil 9 — China sales ($M)($M)
0001934465171,3121,253
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide sales ($M)($M)7
592538619684609539594703617570545713
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — U.S. sales ($M)($M)1
438409427554481423419572490438402567
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — U.S. reported growth YoY (%)(%)
-9.0%2.0%-3.0%-2.0%-3.0%4.0%1.0%4.0%
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — International sales ($M)($M)1
154129192130128116175131127133143146
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — International reported growth YoY (%)(%)
20.0%9.0%-1.0%1.0%-12.0%23.0%-10.0%24.0%
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide reported growth YoY (%)(%)
-3.0%4.0%-3.0%-1.0%-5.0%9.0%-1.0%6.0%8.0%
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-3.0%3.0%-3.0%-2.0%9.0%7.0%8.0%
Varivax (varicella live virus vaccine) — Worldwide sales ($M)($M)2
260235264288240249274301266262252325
Varivax — Worldwide reported growth YoY (%)(%)
8.0%-6.0%-4.0%-10.0%-5.0%-7.0%4.0%11.0%16.0%
Varivax — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
8.0%-7.0%-5.0%-10.0%-4.0%-7.0%5.0%11.0%15.0%
ProQuad (measles, mumps, rubella and varicella virus vaccine) — Worldwide sales ($M)($M)2
235198262273273121203274239204192267
ProQuad — Worldwide reported growth YoY (%)(%)
-14.0%64.0%15.0%-41.0%3.0%7.0%8.0%1.0%
ProQuad — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-15.0%60.0%-1.0%14.0%-40.0%3.0%8.0%7.0%1.0%
M-M-R II (measles, mumps and rubella virus vaccine) — Worldwide sales ($M)($M)2
961059312395168118129113104101122
M-M-R II — Worldwide reported growth YoY (%)(%)
1.0%-38.0%-5.0%-15.0%62.0%5.0%8.0%2.0%-2.0%
M-M-R II — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
1.0%-39.0%-6.0%-16.0%63.0%6.0%9.0%2.0%-4.0%
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — Worldwide sales ($M)($M)4
148202140226229230161239189219176214
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — U.S. sales ($M)($M)1
69123501341361396413799161138182
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — U.S. reported growth YoY (%)(%)
-50.0%-22.0%-1.0%38.0%-14.0%-53.0%-25.0%-33.0%72.0%5.0%
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — International sales ($M)($M)
8078909193929610390583833
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — Worldwide reported growth YoY (%)(%)
-35.0%-13.0%-6.0%21.0%5.0%-9.0%12.0%13.0%106.0%28.0%
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-36.0%-16.0%-7.0%20.0%-9.0%16.0%106.0%26.0%
Capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — Worldwide sales ($M)($M)2
18414227924412910750975047
Capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — U.S. sales ($M)($M)
138118258238129106494700
Capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — International sales ($M)($M)
4523217010000
RotaTeq (rotavirus live oral pentavalent vaccine) — Worldwide sales ($M)($M)4
134206119204121228139193163216185156
RotaTeq (rotavirus live oral pentavalent vaccine) — U.S. sales ($M)($M)1
84165601416016484131107149112108
RotaTeq (rotavirus live oral pentavalent vaccine) — U.S. reported growth YoY (%)(%)
39.0%-28.0%8.0%-44.0%10.0%-25.0%21.0%15.0%-17.0%37.0%-30.0%
RotaTeq (rotavirus live oral pentavalent vaccine) — International sales ($M)($M)1
504259636164556256677348
RotaTeq (rotavirus live oral pentavalent vaccine) — International reported growth YoY (%)(%)
-18.0%8.0%2.0%9.0%-4.0%-25.0%28.0%50.0%-43.0%28.0%-53.0%
RotaTeq (rotavirus live oral pentavalent vaccine) — Worldwide reported growth YoY (%)(%)
10.0%-14.0%6.0%-26.0%5.0%-25.0%24.0%25.0%-27.0%34.0%-39.0%
RotaTeq (rotavirus live oral pentavalent vaccine) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
9.0%-15.0%5.0%-26.0%-25.0%26.0%-27.0%33.0%-39.0%
Vaqta (hepatitis A vaccine, legacy) — Worldwide sales ($M)($M)2
2969
Vaqta (hepatitis A vaccine, legacy) — U.S. sales ($M)($M)
2832
Vaqta (hepatitis A vaccine, legacy) — International sales ($M)($M)
137
Winrevair (sotatercept — PAH activin signaling inhibitor, launched Q2 2024) — Worldwide sales ($M)($M)2
5885254673603362802002001497000
Winrevair (sotatercept — PAH activin signaling inhibitor, launched Q2 2024) — U.S. sales ($M)($M)
52247743233532326819214770000
Winrevair (sotatercept — PAH activin signaling inhibitor, launched Q2 2024) — International sales ($M)($M)
664835251212930000
Ohtuvayre (ensifentrine — COPD maintenance therapy, acquired via Verona Pharma Q4 2025) — Worldwide sales ($M)($M)2
20413100
Ohtuvayre (ensifentrine — COPD maintenance therapy, acquired via Verona Pharma Q4 2025) — U.S. sales ($M)($M)
20413100
Ohtuvayre (ensifentrine — COPD maintenance therapy, acquired via Verona Pharma Q4 2025) — International sales ($M)($M)
0000
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — Worldwide sales ($M)($M)5
1261091291121231061091021069810892
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — U.S. sales ($M)($M)1
1121091121031089710596989010296
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — U.S. reported growth YoY (%)(%)
4.0%7.0%8.0%10.0%8.0%3.0%-1.0%41.0%8.0%20.0%13.0%
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — International sales ($M)($M)1
14017815957886-4
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — International reported growth YoY (%)(%)
-1.0%25.0%89.0%12.0%-27.0%-51.0%
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — Worldwide reported growth YoY (%)(%)
3.0%18.0%9.0%16.0%8.0%1.0%11.0%56.0%-1.0%31.0%5.0%
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
3.0%18.0%9.0%16.0%1.0%56.0%-1.0%31.0%5.0%
Adempas (riociguat — direct Merck territory sales) — Worldwide sales ($M)($M)4
787883828068737272706665
Adempas (riociguat — direct Merck territory sales) — U.S. sales ($M)($M)
000000000000
Adempas (riociguat — direct Merck territory sales) — International sales ($M)($M)
787883828068737272706665
Adempas (riociguat — direct Merck territory sales) — Worldwide reported growth YoY (%)(%)
-2.0%14.0%14.0%10.0%11.0%11.0%18.0%15.0%15.0%
Adempas (riociguat — direct Merck territory sales) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-4.0%9.0%7.0%6.0%9.0%15.0%18.0%11.0%11.0%
Bridion (sugammadex — neuromuscular blockade reversal) — Worldwide sales ($M)($M)4
497472499439461441449420455440429424
Bridion (sugammadex — neuromuscular blockade reversal) — U.S. sales ($M)($M)1
460427451392411378382339351329315265
Bridion (sugammadex — neuromuscular blockade reversal) — U.S. reported growth YoY (%)(%)
12.0%18.0%15.0%17.0%15.0%21.0%28.0%17.0%19.0%22.0%14.0%
Bridion (sugammadex — neuromuscular blockade reversal) — International sales ($M)($M)1
3745494750636781104111113159
Bridion (sugammadex — neuromuscular blockade reversal) — International reported growth YoY (%)(%)
-25.0%-28.0%-42.0%-52.0%-43.0%-41.0%-49.0%-49.0%-47.0%-38.0%-17.0%
Bridion (sugammadex — neuromuscular blockade reversal) — Worldwide reported growth YoY (%)(%)
8.0%11.0%5.0%1.0%5.0%-1.0%-9.0%-10.0%-3.0%
Bridion (sugammadex — neuromuscular blockade reversal) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
8.0%11.0%4.0%1.0%5.0%-8.0%-8.0%-3.0%
Prevymis (letermovir — CMV prophylaxis) — Worldwide sales ($M)($M)4
295272275266228208215208188174175157
Prevymis (letermovir — CMV prophylaxis) — U.S. sales ($M)($M)1
14713513012811510210610190747870
Prevymis (letermovir — CMV prophylaxis) — U.S. reported growth YoY (%)(%)
28.0%23.0%27.0%27.0%37.0%36.0%43.0%47.0%37.0%49.0%43.0%
Prevymis (letermovir — CMV prophylaxis) — International sales ($M)($M)1
148138146138113106109107981009887
Prevymis (letermovir — CMV prophylaxis) — International reported growth YoY (%)(%)
31.0%33.0%29.0%16.0%6.0%12.0%24.0%19.0%33.0%50.0%35.0%
Prevymis (letermovir — CMV prophylaxis) — Worldwide reported growth YoY (%)(%)
29.0%28.0%28.0%21.0%19.0%23.0%32.0%31.0%35.0%49.0%38.0%
Prevymis (letermovir — CMV prophylaxis) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
28.0%26.0%25.0%20.0%23.0%35.0%39.0%49.0%38.0%
Dificid (fidaxomicin — C. difficile infection) — Worldwide sales ($M)($M)4
223425439683799692738774
Dificid (fidaxomicin — C. difficile infection) — U.S. sales ($M)($M)1
112417308372728379687569
Dificid (fidaxomicin — C. difficile infection) — U.S. reported growth YoY (%)(%)
-87.0%-76.0%-64.0%4.0%6.0%-4.0%20.0%16.0%10.0%32.0%-3.0%
Dificid (fidaxomicin — C. difficile infection) — International sales ($M)($M)1
12108131311713125125
Dificid (fidaxomicin — C. difficile infection) — International reported growth YoY (%)(%)
-11.0%13.0%-2.0%8.0%117.0%-42.0%190.0%56.0%49.0%17.0%-20.0%
Dificid (fidaxomicin — C. difficile infection) — Worldwide reported growth YoY (%)(%)
-77.0%-68.0%-55.0%5.0%13.0%-9.0%31.0%20.0%12.0%30.0%-4.0%
Dificid (fidaxomicin — C. difficile infection) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-77.0%-68.0%-55.0%5.0%-9.0%20.0%12.0%30.0%-4.0%
Zerbaxa (ceftolozane and tazobactam) — Worldwide sales ($M)($M)4
778287817470706462566153
Zerbaxa (ceftolozane and tazobactam) — U.S. sales ($M)($M)1
445250494542403933333329
Zerbaxa (ceftolozane and tazobactam) — U.S. reported growth YoY (%)(%)
-3.0%25.0%25.0%35.0%27.0%23.0%34.0%12.0%23.0%31.0%19.0%
Zerbaxa (ceftolozane and tazobactam) — International sales ($M)($M)1
343036322928302628232824
Zerbaxa (ceftolozane and tazobactam) — International reported growth YoY (%)(%)
14.0%23.0%25.0%5.0%20.0%4.0%6.0%17.0%1.0%18.0%27.0%
Zerbaxa (ceftolozane and tazobactam) — Worldwide reported growth YoY (%)(%)
4.0%24.0%25.0%21.0%24.0%14.0%22.0%14.0%13.0%25.0%23.0%
Zerbaxa (ceftolozane and tazobactam) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
2.0%23.0%24.0%21.0%16.0%18.0%15.0%23.0%22.0%
Primaxin (imipenem and cilastatin, legacy) — Worldwide sales ($M)($M)4
3941
Primaxin (imipenem and cilastatin, legacy) — U.S. sales ($M)($M)
-10
Primaxin (imipenem and cilastatin, legacy) — International sales ($M)($M)
3841
Primaxin (imipenem and cilastatin, legacy) — Worldwide reported growth YoY (%)(%)
-28.0%-35.0%
Primaxin (imipenem and cilastatin, legacy) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-28.0%-31.0%
Noxafil (posaconazole, legacy) — Worldwide sales ($M)($M)4
364145564651
Noxafil (posaconazole, legacy) — U.S. sales ($M)($M)1
-210844
Noxafil (posaconazole, legacy) — U.S. reported growth YoY (%)(%)
-149.0%-85.0%-43.0%-72.0%-71.0%
Noxafil (posaconazole, legacy) — International sales ($M)($M)1
374044484347
Noxafil (posaconazole, legacy) — International reported growth YoY (%)(%)
-12.0%-15.0%4.0%-7.0%-3.0%
Noxafil (posaconazole, legacy) — Worldwide reported growth YoY (%)(%)
-23.0%-20.0%-20.0%-7.0%-21.0%-18.0%
Noxafil (posaconazole, legacy) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-17.0%-9.0%4.0%-16.0%-12.0%
Total Diabetes Franchise (Januvia + Janumet) — Worldwide sales ($M)2
Januvia (sitagliptin — DPP-4 inhibitor) — Worldwide sales ($M)($M)4
258367302382372549232278405419547581
Januvia (sitagliptin — DPP-4 inhibitor) — U.S. sales ($M)($M)1
1492521802582163444167177183309328
Januvia (sitagliptin — DPP-4 inhibitor) — U.S. reported growth YoY (%)(%)
-31.0%22.0%88.0%-87.0%-80.0%-27.0%-32.0%6.0%-1.0%
Januvia (sitagliptin — DPP-4 inhibitor) — International sales ($M)($M)1
109116122124155204191211227236239252
Januvia (sitagliptin — DPP-4 inhibitor) — International reported growth YoY (%)(%)
-30.0%-36.0%-42.0%-32.0%-13.0%-20.0%-16.0%-15.0%-16.0%-12.0%-34.0%
Januvia (sitagliptin — DPP-4 inhibitor) — Worldwide reported growth YoY (%)(%)
-31.0%30.0%37.0%-8.0%31.0%-58.0%-52.0%-21.0%-24.0%-2.0%-19.0%
Januvia (sitagliptin — DPP-4 inhibitor) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-30.0%30.0%37.0%-8.0%-56.0%-16.0%-21.0%-2.0%-17.0%
Janumet (sitagliptin and metformin HCl) — Worldwide sales ($M)($M)4
171207199243251247255204224251240255
Janumet (sitagliptin and metformin HCl) — U.S. sales ($M)($M)1
286857786865911517394143
Janumet (sitagliptin and metformin HCl) — U.S. reported growth YoY (%)(%)
-59.0%-37.0%68.0%122.0%-67.0%-80.0%-32.0%-58.0%-52.0%
Janumet (sitagliptin and metformin HCl) — International sales ($M)($M)1
143139142165184182164190208212198211
Janumet (sitagliptin and metformin HCl) — International reported growth YoY (%)(%)
-22.0%-14.0%-13.0%-12.0%-14.0%-17.0%-10.0%-24.0%-22.0%-22.0%-35.0%
Janumet (sitagliptin and metformin HCl) — Worldwide reported growth YoY (%)(%)
-32.0%-22.0%19.0%12.0%-2.0%7.0%-20.0%-37.0%-24.0%-32.0%-39.0%
Janumet (sitagliptin and metformin HCl) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-33.0%-22.0%20.0%14.0%11.0%-32.0%-20.0%-32.0%-38.0%
Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — Worldwide sales ($M)($M)4
5285713883102121383110350193640
Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — U.S. sales ($M)($M)
1161124303532841545100
Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — International sales ($M)($M)1
3124511452678829995305183640
Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — International reported growth YoY (%)(%)
-94.0%-49.0%-62.0%-45.0%-78.0%-52.0%-53.0%-23.0%
Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — Worldwide reported growth YoY (%)(%)
-95.0%-53.0%-64.0%-25.0%-71.0%-37.0%-46.0%-11.0%-77.0%47.0%
Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-95.0%-53.0%-65.0%-27.0%-37.0%-42.0%-5.0%-76.0%51.0%
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — Worldwide sales ($M)($M)4
6059678286909210289111105119
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — U.S. sales ($M)($M)1
363537444851385443505058
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — U.S. reported growth YoY (%)(%)
-26.0%-3.0%-18.0%13.0%2.0%-23.0%-6.0%-24.0%-3.0%
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — International sales ($M)($M)1
242430373839534846615661
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — International reported growth YoY (%)(%)
-36.0%-44.0%-23.0%-18.0%-35.0%-4.0%-21.0%-42.0%-14.0%
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — Worldwide reported growth YoY (%)(%)
-30.0%-27.0%-20.0%-3.0%-19.0%-13.0%-14.0%-35.0%-10.0%
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-31.0%-28.0%-21.0%-4.0%-7.0%-31.0%-7.0%
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — Worldwide sales ($M)($M)4
1017579778367696560565454
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — U.S. sales ($M)($M)1
131014131415141514121213
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — U.S. reported growth YoY (%)(%)
-7.0%-1.0%-13.0%-5.0%28.0%19.0%15.0%13.0%9.0%
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — International sales ($M)($M)1
886565647052555045444240
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — International reported growth YoY (%)(%)
27.0%19.0%29.0%55.0%17.0%30.0%23.0%21.0%34.0%
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — Worldwide reported growth YoY (%)(%)
21.0%15.0%19.0%40.0%19.0%28.0%21.0%19.0%28.0%
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
17.0%9.0%13.0%35.0%29.0%23.0%30.0%
Pifeltro (doravirine — HIV-1 NNRTI) — Worldwide sales ($M)($M)4
42434145404239423337
Pifeltro (doravirine — HIV-1 NNRTI) — U.S. sales ($M)($M)1
26292532263127292327
Pifeltro (doravirine — HIV-1 NNRTI) — U.S. reported growth YoY (%)(%)
-3.0%-7.0%-4.0%8.0%16.0%12.0%-1.0%22.0%
Pifeltro (doravirine — HIV-1 NNRTI) — International sales ($M)($M)1
17141613131212131010
Pifeltro (doravirine — HIV-1 NNRTI) — International reported growth YoY (%)(%)
23.0%21.0%26.0%2.0%29.0%20.0%15.0%25.0%
Pifeltro (doravirine — HIV-1 NNRTI) — Worldwide reported growth YoY (%)(%)
6.0%1.0%5.0%7.0%20.0%14.0%3.0%23.0%
Pifeltro (doravirine — HIV-1 NNRTI) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
4.0%-1.0%4.0%20.0%4.0%23.0%
Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide sales ($M)($M)4
0000543189172184710171
Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — U.S. sales ($M)($M)
0000000000
Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — International sales ($M)($M)
0000-2189172184171179
Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide reported growth YoY (%)(%)
-4.0%2.0%3.0%3.0%
Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-24.0%-2.0%1.0%-2.0%-2.0%
Remicade (infliximab — immunology, legacy ex-U.S. marketing rights) — Worldwide sales ($M)($M)3
000011441353918743
Remicade (infliximab — immunology, legacy ex-U.S. marketing rights) — U.S. sales ($M)($M)
0000000000
Remicade (infliximab — immunology, legacy ex-U.S. marketing rights) — International sales ($M)($M)
0000-14135394345
Remicade (infliximab — immunology, legacy ex-U.S. marketing rights) — Worldwide reported growth YoY (%)(%)
-27.0%-24.0%-1.0%-8.0%
Belsomra (suvorexant — insomnia orexin receptor antagonist) — Worldwide sales ($M)($M)4
49474050457853465458
Belsomra (suvorexant — insomnia orexin receptor antagonist) — U.S. sales ($M)($M)1
22281813192019152123
Belsomra (suvorexant — insomnia orexin receptor antagonist) — U.S. reported growth YoY (%)(%)
18.0%40.0%-1.0%-10.0%-12.0%-12.0%-12.0%-9.0%10.0%12.0%
Belsomra (suvorexant — insomnia orexin receptor antagonist) — International sales ($M)($M)1
27192137265834323335
Belsomra (suvorexant — insomnia orexin receptor antagonist) — International reported growth YoY (%)(%)
1.0%-67.0%-37.0%16.0%-20.0%66.0%-18.0%-21.0%-17.0%-15.0%
Belsomra (suvorexant — insomnia orexin receptor antagonist) — Worldwide reported growth YoY (%)(%)
8.0%-40.0%-24.0%8.0%-17.0%35.0%-16.0%-17.0%-8.0%-6.0%
Belsomra (suvorexant — insomnia orexin receptor antagonist) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
9.0%-40.0%-26.0%-17.0%-8.0%-11.0%-6.0%-4.0%
Other Pharmaceutical Products — Worldwide sales ($M)($M)5
6417747701,004703865699638618632576568
Other Pharmaceutical Products — U.S. sales ($M)($M)1
150166126239184184121167190165137189
Other Pharmaceutical Products — U.S. reported growth YoY (%)(%)
-18.0%4.0%43.0%-28.0%12.0%26.0%13.0%20.0%-8.0%-20.0%2.0%
Other Pharmaceutical Products — International sales ($M)($M)1
489608531716520545581466430467438381
Other Pharmaceutical Products — International reported growth YoY (%)(%)
-6.0%-9.0%54.0%5.0%17.0%24.0%12.0%-4.0%-8.0%11.0%-14.0%
Other Pharmaceutical Products — Worldwide reported growth YoY (%)(%)
-9.0%-6.0%50.0%-6.0%16.0%25.0%13.0%2.0%-8.0%2.0%-9.0%
Other Pharmaceutical Products — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
-9.0%-5.0%49.0%-7.0%25.0%6.0%-6.0%2.0%-7.0%
Upfront & milestone payments received for out-licensed products — Worldwide ($M)($M)
0132271159515151561
Animal Health Segment — Worldwide sales ($M)($M)6
1,7751,7911,5051,6151,6461,5881,3971,4871,4821,5111,2781,400
Animal Health Segment — U.S. sales ($M)($M)1
535448504499502444487455474387462
Animal Health Segment — U.S. reported growth YoY (%)(%)
7.0%1.0%3.0%9.0%6.0%15.0%6.0%-4.0%-2.0%-2.0%-3.0%
Animal Health Segment — International sales ($M)($M)1
1,2401,0561,1121,1471,0869539991,0271,037891938
Animal Health Segment — International reported growth YoY (%)(%)
8.0%11.0%11.0%12.0%5.0%7.0%6.0%5.0%3.0%7.0%5.0%
Animal Health Segment — Worldwide reported growth YoY (%)(%)
8.0%8.0%9.0%11.0%5.0%9.0%6.0%2.0%1.0%4.0%2.0%
Animal Health Segment — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
5.0%6.0%7.0%11.0%13.0%6.0%4.0%4.0%2.0%
Animal Health — Livestock (cattle, poultry, swine & aqua) — Worldwide sales ($M)($M)4
1,0411,0649871,023961924889886837850808874
Animal Health — Livestock (cattle, poultry, swine & aqua) — U.S. sales ($M)($M)1
202211209213190194203194168166158205
Animal Health — Livestock (cattle, poultry, swine & aqua) — U.S. reported growth YoY (%)(%)
6.0%3.0%10.0%13.0%17.0%28.0%-5.0%2.0%-5.0%-16.0%10.0%
Animal Health — Livestock (cattle, poultry, swine & aqua) — International sales ($M)($M)1
838853777811771730686692669683649669
Animal Health — Livestock (cattle, poultry, swine & aqua) — International reported growth YoY (%)(%)
9.0%13.0%17.0%15.0%7.0%6.0%3.0%4.0%1.0%4.0%4.0%
Animal Health — Livestock (cattle, poultry, swine & aqua) — Worldwide reported growth YoY (%)(%)
8.0%11.0%16.0%15.0%9.0%10.0%1.0%4.0%-1.0%5.0%
Animal Health — Livestock (cattle, poultry, swine & aqua) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
6.0%9.0%14.0%16.0%14.0%11.0%4.0%7.0%
Animal Health — Companion Animal (vaccines & parasiticides) — Worldwide sales ($M)($M)5
734727518592685664508601645661470526
Animal Health — Companion Animal (vaccines & parasiticides) — U.S. sales ($M)($M)1
333308239291309308241293287308229257
Animal Health — Companion Animal (vaccines & parasiticides) — U.S. reported growth YoY (%)(%)
8.0%-1.0%-1.0%8.0%5.0%14.0%-7.0%10.0%-11.0%
Animal Health — Companion Animal (vaccines & parasiticides) — International sales ($M)($M)1
402419279301376356267307358354242269
Animal Health — Companion Animal (vaccines & parasiticides) — International reported growth YoY (%)(%)
7.0%4.0%-2.0%5.0%1.0%11.0%14.0%6.0%6.0%16.0%6.0%
Animal Health — Companion Animal (vaccines & parasiticides) — Worldwide reported growth YoY (%)(%)
7.0%2.0%-2.0%6.0%8.0%14.0%-1.0%3.0%13.0%-3.0%
Animal Health — Companion Animal (vaccines & parasiticides) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
5.0%0.0%-3.0%6.0%10.0%1.0%4.0%12.0%-4.0%
Bravecto (fluralaner parasiticides line) — Quarterly sales Q1–Q3 ($M; Q4 not separately disclosed)($M)1
359379262335266235
Bravecto — Worldwide reported growth YoY (%)(%)
7.0%16.0%-1.0%1.0%-3.0%
Pharmaceutical Segment — Worldwide sales ($M)($M)12
14,76014,34914,84315,61114,05013,63814,04214,94314,40814,00613,14114,263
Pharmaceutical Sales — United States ($M)($M)2
8,8278,5128,6629,4938,3287,9277,7288,2277,3996,9366,6987,153
Pharmaceutical Sales — United States share of Pharmaceutical revenue (%)(%)
59.8%59.3%58.4%60.8%59.3%58.1%55.0%55.1%51.4%49.5%51.0%50.1%
Pharmaceutical Segment — U.S. reported growth YoY (%)(%)
6.0%12.0%15.0%13.0%14.0%15.0%15.0%13.0%13.0%14.0%8.0%
Pharmaceutical Segment — Total International sales ($M)($M)
5,9335,8376,1816,1185,7225,7116,3146,7177,0097,0706,4437,110
Pharmaceutical Sales — Europe ($M)($M)1
2,8012,7252,8392,6752,5512,3842,4982,6202,5722,5552,4912,497
Pharmaceutical Sales — Europe share of Pharmaceutical revenue (%)(%)
19.0%19.0%19.1%17.1%18.2%17.5%17.8%17.5%17.9%18.2%19.0%17.5%
Pharmaceutical Sales — China ($M)($M)1
3683533643774076688649961,7901,7441,4561,674
Pharmaceutical Sales — China share of Pharmaceutical revenue (%)(%)
2.5%2.5%2.5%2.4%2.9%4.9%6.2%6.7%12.4%12.5%11.1%11.7%
Pharmaceutical Sales — Japan ($M)($M)1
5585356846936046518139196648026291,062
Pharmaceutical Sales — Japan share of Pharmaceutical revenue (%)(%)
3.8%3.7%4.6%4.4%4.3%4.8%5.8%6.2%4.6%5.7%4.8%7.4%
Pharmaceutical Sales — Asia Pacific (other than China and Japan) ($M)($M)1
636569586593609535612669595580616636
Pharmaceutical Sales — Asia Pacific (other than China and Japan) share of Pharmaceutical revenue (%)(%)
4.3%4.0%4.0%3.8%4.3%3.9%4.4%4.5%4.1%4.1%4.7%4.5%
Pharmaceutical Sales — Latin America ($M)($M)1
636624644691654589680730661601596696
Pharmaceutical Sales — Latin America share of Pharmaceutical revenue (%)(%)
4.3%4.3%4.3%4.4%4.7%4.3%4.8%4.9%4.6%4.3%4.5%4.9%
Pharmaceutical Sales — Eastern Europe / Middle East / Africa ($M)($M)1
408413348365451435348400353395299301
Pharmaceutical Sales — Eastern Europe / Middle East / Africa share of Pharmaceutical revenue (%)(%)
2.8%2.9%2.3%2.3%3.2%3.2%2.5%2.7%2.4%2.8%2.3%2.1%
Pharmaceutical Sales — Canada ($M)($M)1
154137153134135125144133143138138133
Pharmaceutical Sales — Canada share of Pharmaceutical revenue (%)(%)
1.0%1.0%1.0%0.9%1.0%0.9%1.0%0.9%1.0%1.0%1.1%0.9%
Pharmaceutical Sales — Other Countries ($M)($M)1
372481563590311324355249231255218111
Pharmaceutical Sales — Other Countries share of Pharmaceutical revenue (%)(%)
2.5%3.3%3.8%3.9%2.1%2.4%2.5%1.5%1.6%1.9%1.5%0.9%
Pharmaceutical Segment — Worldwide reported growth YoY (%)(%)
5.0%6.0%4.0%-2.0%-3.0%7.0%5.0%7.0%10.0%8.0%10.0%
Pharmaceutical Segment — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
4.0%4.0%3.0%-3.0%8.0%11.0%13.0%8.0%11.0%
Total Company Sales — Worldwide ($M)($M)5
16,60716,28616,40017,27615,80615,52915,62416,65716,11215,77514,63015,962
Total Company Sales — United States ($M)($M)1
9,3679,1649,13910,0128,8368,5228,1888,7367,8767,4787,0887,715
Total Company Sales — U.S. reported growth YoY (%)(%)
6.0%12.0%15.0%12.0%14.0%16.0%13.0%12.0%12.0%13.0%5.0%
Total Company Sales — International ($M)($M)1
7,2407,1227,2617,2646,9697,0077,4367,9228,2368,2977,5428,247
Total Company Sales — International reported growth YoY (%)(%)
4.0%-2.0%-8.0%-15.0%-16.0%-1.0%-4.0%3.0%6.0%8.0%
Other Revenues (alliance, royalty & third-party supply) — Worldwide ($M)($M)2
721465250110303185227222258211299
Other Revenues — U.S. ($M)($M)
52915993162222683100
Other Revenues — International ($M)($M)
672434100210169206200190208199
Total Company Sales — Worldwide reported growth YoY (%)(%)
5.0%5.0%4.0%-2.0%-2.0%7.0%4.0%7.0%9.0%6.0%7.0%
Total Company Sales — Worldwide constant-currency (ex-exchange) growth YoY (%)(%)
4.0%4.0%3.0%-2.0%9.0%11.0%12.0%7.0%9.0%
U.S. Aggregate Customer Discounts (Chargebacks & Rebates) Provision ($M)($M)
2,5002,5002,8002,6002,5002,1003,2003,6003,3003,2003,1003,100
Collaboration — AstraZeneca (Lynparza & Koselugo Oncology Alliance) ($M)($M)6
8484858486831338282828182
AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Current receivables from partner ($M)($M)
375401451436411358424375349334341
AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Noncurrent receivables from partner ($M)($M)
1251251250
AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Current payables / liabilities to partner ($M)($M)
612641215713615615617256257
AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Cost of sales profit-sharing & manufacturing ($M)($M)
8484858486831338282828182
AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Net R&D cost-sharing expense ($M)($M)
95531612201918201423
AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Commercialization / SG&A expense sharing ($M)($M)
252430314032443943394944
Collaboration — Eisai Co., Ltd. (Lenvima Oncology Alliance) ($M)($M)4
1313606060606060606061137
Eisai Co., Ltd. (Lenvima Oncology Alliance) — Current receivables from partner ($M)($M)
281252271258265263257252245255226
Eisai Co., Ltd. (Lenvima Oncology Alliance) — Cost of sales profit-sharing & manufacturing ($M)($M)
1313606060606060606061137
Eisai Co., Ltd. (Lenvima Oncology Alliance) — Net R&D cost-sharing expense ($M)($M)
021235346855
Eisai Co., Ltd. (Lenvima Oncology Alliance) — Commercialization / SG&A expense sharing ($M)($M)
292735333531394041394446
Collaboration — Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) ($M)($M)5
676766716158625961625953
Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Current receivables from partner ($M)($M)
166162167168173160160166170155156
Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Current payables / liabilities to partner ($M)($M)
868781938883828281748082
Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Cost of sales profit-sharing & manufacturing ($M)($M)
676766716158625961625953
Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Net R&D cost-sharing expense ($M)($M)
10171112024202728281426
Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Commercialization / SG&A expense sharing ($M)($M)
111217222929232926333133
Collaboration — Daiichi Sankyo (3 DXd ADC Oncology Programs) ($M)($M)4
181160-1671931280065695,5000
Daiichi Sankyo (3 DXd ADC Oncology Programs) — Current receivables from partner ($M)($M)
27221517211380
Daiichi Sankyo (3 DXd ADC Oncology Programs) — Current payables / liabilities to partner ($M)($M)
10085113869850803817811801817800
Daiichi Sankyo (3 DXd ADC Oncology Programs) — Net R&D cost-sharing expense ($M)($M)
1811601451101931281249465695,5000
Daiichi Sankyo (3 DXd ADC Oncology Programs) — Commercialization / SG&A expense sharing ($M)($M)
121278495514330
Collaboration — Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) ($M)($M)4
94901039690861039393696566
Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) — Current receivables from partner ($M)($M)
1540235232228198172135110
Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) — Current payables / liabilities to partner ($M)($M)
00131322375768737263
Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) — Net R&D cost-sharing expense ($M)($M)
94901039690861039393696566
Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) — Commercialization / SG&A expense sharing ($M)($M)
988766554222
Collaboration — Ridgeback Biotherapeutics (Lagevrio Antiviral Alliance) ($M)($M)2
145457814453632049619190348
Ridgeback Biotherapeutics (Lagevrio Antiviral Alliance) — Cost of sales profit-sharing & manufacturing ($M)($M)
145457814453632049619190348
Ridgeback Biotherapeutics (Lagevrio Antiviral Alliance) — Commercialization / SG&A expense sharing ($M)($M)
91115111413141116162521
Research & Development Expense — Pharmaceutical Segment ($M)($M)3
0000000000
Research & Development Expense — Animal Health Segment ($M)($M)
12011212511811095109959190
Merck Research Laboratories (MRL) Direct Human Health R&D ($B)
2.80
Acquired In-Process R&D (IPR&D) & Asset Acquisition Charges ($M)($M)
5,2718,54000007002,100065610,2170
Non-GAAP Diluted Earnings per Share ($)($)9
-0.13-1.282.042.582.132.221.721.572.282.070.032.13
Non-GAAP Net Income Attributable to Merck & Co., Inc. ($M)($M)
-1,005-3,1565,0886,4485,3665,6114,3723,9855,8095,279665,427
Non-GAAP Income Before Taxes ($M)($M)3
550-2,2026,0107,4506,3116,5485,2205,1066,7676,296-1,5736,391
Total Pre-Tax Non-GAAP Adjustments ($M)($M)
-1,233-1,332-2,590344-1,312107-1,050-1,0164911661
Acquisition & Divestiture-Related Pre-Tax Charges ($M)($M)
1911,0461,107611,233
Restructuring Pre-Tax Charges ($M)($M)
1,2331801,2771,31261
Non-GAAP Cost of Sales ($M)($M)1
3,1442,9443,3243,1242,8162,7633,0063,2493,0732,9613,3403,679
Cost of Sales Non-GAAP Adjustments (Intangible Amortization & Restructuring) ($M)($M)
1,2511,2512,227731741656822831672579571585
Non-GAAP Selling, General and Administrative (SG&A) Expense ($M)($M)
2,8872,6682,8482,5992,6332,5292,8192,6572,6842,4572,7512,462
Non-GAAP Research and Development (R&D) Expense ($M)($M)
9,73612,5583,9923,9973,9923,6144,5745,8383,4803,9748,8383,297
Non-GAAP Other (Income) Expense, Net ($M)($M)
290318226531108174133
Non-GAAP Income Tax Provision ($M)($M)
8829579231,0009449318461,1179521,012959
Non-GAAP Effective Income Tax Rate (%)(%)
160.3%-43.5%15.4%13.4%15.0%14.2%16.2%21.9%14.1%16.1%114.2%15.0%
GAAP Effective Income Tax Rate (%)(%)
-95.9%-20.1%13.4%14.2%11.4%13.9%10.2%22.7%9.1%15.9%40.1%15.5%
Other (Income) Expense Breakdown — Interest Income ($M)($M)5
-35-69-96-69-109-146-127-69-73-70-73
Other (Income) Expense Breakdown — Interest Expense ($M)($M)
525412327305313328330310303310317
Other (Income) Expense Breakdown — Foreign Exchange Losses ($M)($M)
37995678904933608316285
Other (Income) Expense Breakdown — (Income) Loss on Equity Securities, Net ($M)($M)
-242196-373-100-9015631-56-143-9933
Other (Income) Expense Breakdown — Net Periodic Defined Benefit Plan (Credit) Cost ($M)($M)
-127-163-152-152-148-157-157-159-160-134-138
Other (Income) Expense Breakdown — Other, Net ($M)($M)
-59-43-69-91-104-272-44-43-91-98
Restructuring Programs — Total Period Charges Across All Programs ($M)($M)3
3344661,277390779105187279176246401199
Restructuring Programs — Total Ending Accrual Reserve ($M)($M)
557564651687736712567
2024 Restructuring Program (Supply Network & Commercial Optimization) — Total Period Charges Incurred ($M)($M)5
16214821688130105187279177246
2024 Restructuring Program (Supply Network & Commercial Optimization) — Expected Total Program Cost ($M)($M)
4,0004,0004,0004,0004,0004,0004,0004,0004,0004,0004,000
2024 Restructuring Program (Supply Network & Commercial Optimization) — Cumulative Charges Incurred Since Inception ($M)($M)
1,9001,8001,6001,4001,3001,2001,100892613436
2024 Restructuring Program (Supply Network & Commercial Optimization) — Ending Accrual Reserve Balance ($M)($M)
408448506499548564712
2024 Restructuring Program (Supply Network & Commercial Optimization) — Recorded in Cost of Sales ($M)($M)
999311338653612119266116
2024 Restructuring Program (Supply Network & Commercial Optimization) — Recorded in Restructuring Line Item ($M)($M)
6355103506469515680123
2019 Restructuring Program (legacy) — Total Period Charges Incurred ($M)($M)4
211199
2019 Restructuring Program (legacy) — Ending Accrual Reserve Balance ($M)($M)
597
2019 Restructuring Program (legacy) — Recorded in Cost of Sales ($M)($M)
5533
2019 Restructuring Program (legacy) — Recorded in R&D ($M)($M)
00
2019 Restructuring Program (legacy) — Recorded in Restructuring Line Item ($M)($M)
127126
Total Inventories — Current & Noncurrent Net ($M)($M)4
12,58812,67412,33911,85611,48310,75210,30210,2399,9259,9239,7069,282
Current Inventories, Net ($M)($M)
6,2076,4796,6586,4446,6016,1966,1096,2446,4696,5106,3586,131
Noncurrent Inventories included in Other Assets — Long-Term ($M)($M)
5,9005,8005,5005,2004,3004,0003,8003,7003,2002,6002,6002,400
Total Gross Inventories before LIFO Reserve ($M)($M)3
13,68913,68113,25112,73912,34211,59811,14211,00110,61210,54410,2689,751
Inventories — Finished Goods ($M)($M)
2,1862,2112,2752,2492,1422,1292,0221,9391,8891,9021,9541,840
Inventories — Raw Materials and Work in Process ($M)($M)
11,19411,13610,64510,1659,8889,1798,8318,7808,4568,3668,037
Inventories — Supplies ($M)($M)
309334331325312290289282267276277281
Inventories — LIFO Reserve Reduction ($M)($M)
1,1011,007912883859846840762687621562469
Finite-Lived Intangible Assets — Products & Developed Technology, Net ($M)1
Product Intangible Asset Carrying Value — Adempas (riociguat) ($M)($M)
203239280312348353372431445533
U.S. Defined Benefit Pension Plans — Funded Status ($M)4
U.S. Defined Benefit Pension Plans — Service Cost ($M)($M)
989899100908910010086868788
U.S. Defined Benefit Pension Plans — Interest Cost ($M)($M)
145145144143141141134134134134130130
U.S. Defined Benefit Pension Plans — Expected Return on Plan Assets ($M)($M)
207207210210210210205206207207182182
U.S. Defined Benefit Pension Plans — Net Periodic Benefit Cost (Credit) ($M)($M)
656651583433424123264137
International Defined Benefit Pension Plans — Funded Status ($M)4
International Defined Benefit Pension Plans — Service Cost ($M)($M)
494857576054616060614848
International Defined Benefit Pension Plans — Interest Cost ($M)($M)
798178787571747473747476
International Defined Benefit Pension Plans — Expected Return on Plan Assets ($M)($M)
158161159159152143138139137139127131
International Defined Benefit Pension Plans — Net Periodic Benefit Cost (Credit) ($M)($M)
-35-22-36-41-19-19-5-7-6-6-15-14
Other Postretirement Benefit (OPEB) Plans — Funded Status ($M)4
Other Postretirement Benefit (OPEB) Plans — Service Cost ($M)($M)
111189910778888
Other Postretirement Benefit (OPEB) Plans — Interest Cost ($M)($M)
161615151616141414141616
Other Postretirement Benefit (OPEB) Plans — Expected Return on Plan Assets ($M)($M)
141411131314202020201616
Other Postretirement Benefit (OPEB) Plans — Net Periodic Benefit Cost (Credit) ($M)($M)
-4-3-13-11-8-8-19-24-21-21-15-15
Organon & Co. — Total Revenues ($M)($M)20
1,5581,4601,5071,6021,5941,5131,5921,5821,6071,6221,5981,519
Organon & Co. — Revenues from Related Party (Merck & Co., Inc. Transition/Supply) ($M)($M)
13,000,00013,000,00014,000,00018,000,00019,000,00018,000,00026,000,00025,000,00028,000,00029,000,00027,000,00028,000,000
Organon Revenue — United States ($M)($M)
398,000,000358,000,000372,000,000406,000,000414,000,000412,000,000416,000,000398,000,000388,000,000371,000,000411,000,000370,000,000
Organon Revenue — Total International ($M)($M)
1,160,000,0001,102,000,0001,135,000,0001,196,000,0001,180,000,0001,101,000,0001,176,000,0001,184,000,0001,219,000,0001,251,000,0001,187,000,0001,149,000,000
Organon Revenue — Europe and Canada ($M)($M)
432,000,000412,000,000406,000,000417,000,000419,000,000376,000,000420,000,000436,000,000457,000,000450,000,000414,000,000392,000,000
Organon Revenue — Asia Pacific and Japan ($M)($M)
232,000,000226,000,000248,000,000251,000,000250,000,000251,000,000244,000,000260,000,000260,000,000287,000,000260,000,000284,000,000
Organon Revenue — China ($M)($M)
208,000,000194,000,000202,000,000219,000,000204,000,000204,000,000213,000,000212,000,000216,000,000206,000,000203,000,000202,000,000
Organon Revenue — Latin America, Middle East, Russia and Africa (LAMERA) ($M)($M)
269,000,000247,000,000262,000,000286,000,000285,000,000240,000,000266,000,000243,000,000251,000,000274,000,000278,000,000239,000,000
Organon Revenue — Other ($M)($M)
19,000,00023,000,00017,000,00023,000,00022,000,00030,000,00033,000,00033,000,00035,000,00034,000,00032,000,00032,000,000
Organon & Co. — Gross Profit ($M)($M)
847783741857874841896923939957915907
Organon & Co. — Cost of Sales ($M)($M)
711677766745720672696659668665683612
Organon & Co. — Selling, General and Administrative (SG&A) ($M)($M)
434424433415453420470422437431469538
Organon & Co. — Restructuring Charges ($M)($M)
0317028680023580
Organon & Co. — Net Income ($M)($M)
108146-2051601458710935919520154658
Organon & Co. — Diluted EPS ($)($)
0.400.550.610.560.331.380.750.780.23
Organon & Co. — Operating Cash Flow ($M)($M)
1072251412642207539014133276397261
Organon & Co. — Capital Expenditures ($M)($M)
423745463932554232467955
Organon & Co. — Cash and Cash Equivalents ($M)($M)
1,1321,116574672599547675763704575693414
Organon & Co. — Inventories ($M)($M)
1,3511,3731,4061,4881,4541,3621,3211,3831,2871,2631,3151,186
Organon & Co. — Total Assets ($M)($M)
13,17812,99612,86713,55213,50013,15613,10112,75212,15411,89112,05811,012
Organon & Co. — Long-Term Debt ($M)($M)
8,4798,5538,6288,7838,7818,9368,8608,7398,6478,7058,7518,646
Organon — Nexplanon / Implanon NXT (contraceptive implant) Worldwide sales ($M)($M)2
230,000,000201,000,000210,000,000223,000,000240,000,000248,000,000259,000,000243,000,000242,000,000220,000,000231,000,000220,000,000
Organon — Nexplanon / Implanon NXT (contraceptive implant) U.S. sales ($M)($M)
129,000,000127,000,000124,000,000146,000,000163,000,000176,000,000175,000,000172,000,000171,000,000153,000,000154,000,000146,000,000
Organon — Nexplanon / Implanon NXT (contraceptive implant) International sales ($M)($M)
101,000,00074,000,00086,000,00077,000,00077,000,00072,000,00084,000,00070,000,00070,000,00067,000,00076,000,00074,000,000
Organon — NuvaRing (contraceptive vaginal ring) Worldwide sales ($M)($M)2
27,000,00024,000,00016,000,00026,000,00028,000,00022,000,00025,000,00023,000,00029,000,00038,000,00039,000,00043,000,000
Organon — NuvaRing (contraceptive vaginal ring) U.S. sales ($M)($M)
9,000,0006,000,000-2,000,0009,000,0007,000,0006,000,0006,000,0007,000,00010,000,00016,000,00020,000,00023,000,000
Organon — NuvaRing (contraceptive vaginal ring) International sales ($M)($M)
18,000,00018,000,00018,000,00017,000,00021,000,00016,000,00018,000,00017,000,00019,000,00022,000,00019,000,00020,000,000
Organon — Follistim AQ / Puregon (fertility) Worldwide sales ($M)($M)2
59,000,00061,000,00058,000,00064,000,00074,000,00069,000,00066,000,00063,000,00062,000,00046,000,00083,000,00054,000,000
Organon — Follistim AQ / Puregon (fertility) U.S. sales ($M)($M)
17,000,00021,000,00023,000,00024,000,00030,000,00035,000,00025,000,00026,000,00022,000,00011,000,00051,000,00022,000,000
Organon — Follistim AQ / Puregon (fertility) International sales ($M)($M)
43,000,00039,000,00035,000,00040,000,00043,000,00034,000,00039,000,00037,000,00040,000,00035,000,00031,000,00032,000,000
Organon — Marvelon / Mercilon (oral contraceptives) Worldwide sales ($M)($M)2
32,000,00026,000,00024,000,00031,000,00033,000,00039,000,00031,000,00029,000,00041,000,00033,000,00037,000,00030,000,000
Organon — Marvelon / Mercilon (oral contraceptives) U.S. sales ($M)($M)
000000000000
Organon — Marvelon / Mercilon (oral contraceptives) International sales ($M)($M)
32,000,00026,000,00024,000,00031,000,00033,000,00039,000,00031,000,00029,000,00041,000,00033,000,00037,000,00030,000,000
Organon — Jada System (postpartum hemorrhage device) Worldwide sales ($M)($M)2
05,000,00020,000,00020,000,00018,000,00015,000,00018,000,00016,000,00014,000,00013,000,00012,000,00013,000,000
Organon — Jada System (postpartum hemorrhage device) U.S. sales ($M)($M)
05,000,00020,000,00020,000,00018,000,00015,000,00018,000,00015,000,00014,000,00013,000,00013,000,00012,000,000
Organon — Jada System (postpartum hemorrhage device) International sales ($M)($M)
000000000000
Organon — Renflexis (infliximab-abda biosimilar) Worldwide sales ($M)($M)2
65,000,00057,000,00061,000,00070,000,00063,000,00057,000,00064,000,00072,000,00069,000,00069,000,00077,000,00069,000,000
Organon — Renflexis (infliximab-abda biosimilar) U.S. sales ($M)($M)
44,000,00042,000,00042,000,00051,000,00046,000,00044,000,00052,000,00056,000,00056,000,00055,000,00062,000,00057,000,000
Organon — Renflexis (infliximab-abda biosimilar) International sales ($M)($M)
21,000,00015,000,00020,000,00019,000,00017,000,00012,000,00012,000,00016,000,00013,000,00014,000,00014,000,00012,000,000
Organon — Ontruzant (trastuzumab-dttb biosimilar) Worldwide sales ($M)($M)2
6,000,0005,000,00019,000,00031,000,00031,000,00018,000,00034,000,00020,000,00048,000,00039,000,00062,000,00040,000,000
Organon — Ontruzant (trastuzumab-dttb biosimilar) U.S. sales ($M)($M)
5,000,0004,000,0003,000,0004,000,0005,000,0004,000,0006,000,0005,000,00010,000,0008,000,00010,000,00011,000,000
Organon — Ontruzant (trastuzumab-dttb biosimilar) International sales ($M)($M)
1,000,0001,000,00016,000,00028,000,00026,000,00014,000,00028,000,00015,000,00038,000,00031,000,00052,000,00028,000,000
Organon — Brenzys (etanercept biosimilar) Worldwide sales ($M)($M)2
14,000,00020,000,00021,000,00023,000,00022,000,00014,000,00014,000,00027,000,00012,000,00024,000,00028,000,00013,000,000
Organon — Brenzys (etanercept biosimilar) U.S. sales ($M)($M)
000000000000
Organon — Brenzys (etanercept biosimilar) International sales ($M)($M)
14,000,00020,000,00021,000,00023,000,00022,000,00014,000,00014,000,00027,000,00012,000,00024,000,00028,000,00013,000,000
Organon — Hadlima (adalimumab-bwwd biosimilar) Worldwide sales ($M)($M)2
79,000,00067,000,00069,000,00063,000,00050,000,00047,000,00044,000,00040,000,00028,000,00030,000,00024,000,0008,000,000
Organon — Hadlima (adalimumab-bwwd biosimilar) U.S. sales ($M)($M)
55,000,00051,000,00050,000,00047,000,00036,000,00033,000,00033,000,00029,000,00020,000,00022,000,00015,000,0002,000,000
Organon — Hadlima (adalimumab-bwwd biosimilar) International sales ($M)($M)
24,000,00016,000,00018,000,00016,000,00014,000,00014,000,00011,000,00011,000,0008,000,0008,000,0008,000,0006,000,000
Organon — Zetia (ezetimibe) Worldwide sales ($M)($M)2
96,000,00087,000,00090,000,00093,000,00074,000,00085,000,00077,000,00081,000,00075,000,00084,000,00069,000,00069,000,000
Organon — Zetia (ezetimibe) U.S. sales ($M)($M)
2,000,0001,000,0001,000,0001,000,0001,000,0001,000,0002,000,0002,000,0002,000,0002,000,0003,000,0002,000,000
Organon — Zetia (ezetimibe) International sales ($M)($M)
95,000,00086,000,00089,000,00091,000,00072,000,00084,000,00075,000,00080,000,00073,000,00082,000,00066,000,00068,000,000
Organon — Vytorin (ezetimibe/simvastatin) Worldwide sales ($M)($M)2
21,000,00021,000,00025,000,00025,000,00027,000,00023,000,00026,000,00026,000,00028,000,00028,000,00029,000,00033,000,000
Organon — Vytorin (ezetimibe/simvastatin) U.S. sales ($M)($M)
1,000,0001,000,0001,000,0001,000,0001,000,0001,000,0002,000,0001,000,0002,000,0001,000,0001,000,0002,000,000
Organon — Vytorin (ezetimibe/simvastatin) International sales ($M)($M)
20,000,00020,000,00024,000,00025,000,00026,000,00022,000,00024,000,00025,000,00026,000,00027,000,00029,000,00031,000,000
Organon — Atozet (ezetimibe/atorvastatin) Worldwide sales ($M)($M)2
80,000,00085,000,00067,000,00095,000,00086,000,00077,000,00077,000,000125,000,000140,000,000132,000,000122,000,000126,000,000
Organon — Atozet (ezetimibe/atorvastatin) U.S. sales ($M)($M)
000000000000
Organon — Atozet (ezetimibe/atorvastatin) International sales ($M)($M)
80,000,00085,000,00067,000,00095,000,00086,000,00077,000,00077,000,000125,000,000140,000,000132,000,000122,000,000126,000,000
Organon — Rosuzet (ezetimibe/rosuvastatin) Worldwide sales ($M)($M)2
5,000,0006,000,0008,000,0006,000,0006,000,0004,000,00013,000,00011,000,0009,000,00016,000,00018,000,00017,000,000
Organon — Rosuzet (ezetimibe/rosuvastatin) U.S. sales ($M)($M)
000000000000
Organon — Rosuzet (ezetimibe/rosuvastatin) International sales ($M)($M)
5,000,0006,000,0008,000,0006,000,0006,000,0004,000,00013,000,00011,000,0009,000,00016,000,00018,000,00017,000,000
Organon — Cozaar / Hyzaar (losartan) Worldwide sales ($M)($M)2
50,000,00057,000,00053,000,00055,000,00056,000,00055,000,00057,000,00059,000,00060,000,00067,000,00056,000,00068,000,000
Organon — Cozaar / Hyzaar (losartan) U.S. sales ($M)($M)
2,000,0002,000,0002,000,0002,000,0002,000,0002,000,0002,000,0002,000,0002,000,0003,000,0002,000,0003,000,000
Organon — Cozaar / Hyzaar (losartan) International sales ($M)($M)
48,000,00055,000,00051,000,00053,000,00054,000,00053,000,00055,000,00057,000,00058,000,00065,000,00055,000,00065,000,000
Organon — Singulair (montelukast) Worldwide sales ($M)($M)2
48,000,00040,000,00059,000,00053,000,00066,000,00074,000,00084,000,00085,000,00093,000,00098,000,000114,000,00091,000,000
Organon — Singulair (montelukast) U.S. sales ($M)($M)
2,000,0002,000,0002,000,0002,000,0002,000,0002,000,0002,000,0002,000,0002,000,0002,000,0003,000,0003,000,000
Organon — Singulair (montelukast) International sales ($M)($M)
46,000,00038,000,00057,000,00051,000,00064,000,00072,000,00082,000,00083,000,00090,000,00095,000,000111,000,00088,000,000
Organon — Nasonex (mometasone) Worldwide sales ($M)($M)2
58,000,00065,000,00065,000,00060,000,00066,000,00072,000,00076,000,00063,000,00060,000,00077,000,00069,000,00060,000,000
Organon — Nasonex (mometasone) U.S. sales ($M)($M)
000000000000
Organon — Nasonex (mometasone) International sales ($M)($M)
58,000,00065,000,00064,000,00060,000,00066,000,00071,000,00076,000,00063,000,00060,000,00077,000,00069,000,00060,000,000
Organon — Dulera (mometasone/formoterol) Worldwide sales ($M)($M)2
41,000,00035,000,00035,000,00034,000,00041,000,00043,000,00052,000,00048,000,00047,000,00056,000,00050,000,00049,000,000
Organon — Dulera (mometasone/formoterol) U.S. sales ($M)($M)
30,000,00023,000,00024,000,00024,000,00032,000,00034,000,00042,000,00038,000,00039,000,00043,000,00040,000,00040,000,000
Organon — Dulera (mometasone/formoterol) International sales ($M)($M)
11,000,00012,000,00011,000,00010,000,0009,000,00010,000,00011,000,00010,000,0008,000,00013,000,00010,000,0009,000,000
Organon — Clarinex (desloratadine) Worldwide sales ($M)($M)2
30,000,00031,000,00030,000,00025,000,00034,000,00034,000,00027,000,00027,000,00035,000,00037,000,00029,000,00028,000,000
Organon — Clarinex (desloratadine) U.S. sales ($M)($M)
1,000,0001,000,0001,000,0001,000,0001,000,00001,000,0001,000,0001,000,0001,000,0001,000,0002,000,000
Organon — Clarinex (desloratadine) International sales ($M)($M)
30,000,00030,000,00029,000,00025,000,00033,000,00034,000,00028,000,00026,000,00035,000,00036,000,00029,000,00026,000,000
Organon — Arcoxia (etoricoxib) Worldwide sales ($M)($M)2
69,000,00059,000,00070,000,00071,000,00063,000,00062,000,00059,000,00069,000,00068,000,00075,000,00050,000,00064,000,000
Organon — Arcoxia (etoricoxib) U.S. sales ($M)($M)
000000000000
Organon — Arcoxia (etoricoxib) International sales ($M)($M)
69,000,00059,000,00070,000,00071,000,00063,000,00062,000,00059,000,00069,000,00068,000,00075,000,00050,000,00064,000,000
Organon — Fosamax (alendronate) Worldwide sales ($M)($M)2
25,000,00029,000,00036,000,00040,000,00034,000,00033,000,00039,000,00038,000,00035,000,00040,000,00036,000,00041,000,000
Organon — Fosamax (alendronate) U.S. sales ($M)($M)
1,000,00000001,000,00001,000,0001,000,0001,000,0001,000,0001,000,000
Organon — Fosamax (alendronate) International sales ($M)($M)
24,000,00029,000,00035,000,00040,000,00034,000,00032,000,00038,000,00037,000,00034,000,00038,000,00035,000,00040,000,000
Organon — Diprospan (betamethasone) Worldwide sales ($M)($M)2
44,000,00035,000,00038,000,00041,000,00041,000,00030,000,00037,000,00037,000,00037,000,00029,000,00033,000,00031,000,000
Organon — Diprospan (betamethasone) U.S. sales ($M)($M)
000000000000
Organon — Diprospan (betamethasone) International sales ($M)($M)
44,000,00035,000,00038,000,00041,000,00041,000,00030,000,00037,000,00037,000,00037,000,00029,000,00033,000,00031,000,000
Organon — Proscar (finasteride — BPH) Worldwide sales ($M)($M)2
20,000,00026,000,00024,000,00027,000,00022,000,00024,000,00022,000,00023,000,00023,000,00026,000,00020,000,00025,000,000
Organon — Proscar (finasteride — BPH) U.S. sales ($M)($M)
000000000000
Organon — Proscar (finasteride — BPH) International sales ($M)($M)
20,000,00026,000,00023,000,00027,000,00022,000,00024,000,00022,000,00023,000,00023,000,00026,000,00020,000,00025,000,000
Organon — Propecia (finasteride — alopecia) Worldwide sales ($M)($M)2
36,000,00030,000,00028,000,00033,000,00032,000,00026,000,00032,000,00028,000,00028,000,00023,000,00033,000,00022,000,000
Organon — Propecia (finasteride — alopecia) U.S. sales ($M)($M)
2,000,0001,000,0002,000,0002,000,0001,000,0001,000,0001,000,0002,000,0002,000,0002,000,0002,000,0002,000,000
Organon — Propecia (finasteride — alopecia) International sales ($M)($M)
34,000,00028,000,00026,000,00031,000,00030,000,00024,000,00031,000,00027,000,00027,000,00021,000,00032,000,00021,000,000
Organon — Vtama (tapinarof cream, acquired via Dermavant Q4 2024) Worldwide sales ($M)($M)2
35,000,00025,000,00039,000,00034,000,00031,000,00024,000,00012,000,000000
Organon — Vtama (tapinarof cream, acquired via Dermavant Q4 2024) U.S. sales ($M)($M)
34,000,00023,000,00031,000,00031,000,00029,000,00020,000,00010,000,000000
Organon — Vtama (tapinarof cream, acquired via Dermavant Q4 2024) International sales ($M)($M)
1,000,0002,000,0008,000,0003,000,0002,000,0004,000,0001,000,000000
U.S. Real Personal Consumption Expenditures — Health Care (SAAR, $B Chained 2017 Dollars)
3,790.303,699.903,667.003,614.803,529.803,464.703,417.803,358.203,288.203,244.403,159.403,079.00
DB Segment Context — Pharmaceutical Segment Revenue ($M)($M)7
14,76014,34914,84315,61114,05013,63814,04214,94314,40814,00613,14114,263
Pharmaceutical Segment — Cost of Sales ($M)($M)
1,7311,5531,8411,6641,6011,5731,5091,9041,7081,706
Pharmaceutical Segment — SG&A Expense ($M)($M)
1,4371,3321,5471,4691,3671,4021,6661,5191,5141,429
Pharmaceutical Segment — Segment Profit / Pretax Income ($M)($M)
11,61211,51911,49012,53811,10310,71210,88211,54711,20010,9049,48010,407
Animal Health Segment — Revenue ($M)($M)
1,7751,7911,5051,6151,6461,5881,3971,4871,4821,5111,2781,400
Animal Health Segment — Cost of Sales ($M)($M)
715675681710659600631613612613
Animal Health Segment — SG&A Expense ($M)($M)
304282303277284260293268270252
Animal Health Segment — Segment Profit / Pretax Income ($M)($M)
636722394511593634364510508555284421
DB Geographic Context — Consolidated U.S. Revenue ($M)($M)14
9,3679,1649,13910,0128,8368,5228,1888,7367,8767,4787,0877,715
Consolidated EMEA Revenue ($M)($M)
3,9203,8863,7913,6803,6593,4543,3803,5833,5153,5633,2763,327
Consolidated China Revenue ($M)($M)
4083903864054467028881,0171,8171,7721,4801,694
Consolidated Japan Revenue ($M)($M)
5775557047126266698359386868216501,081
Consolidated Asia Pacific (ex-China & Japan) Revenue ($M)($M)
820738745764785689764823748724750781
Consolidated Latin America Revenue ($M)($M)
875874854905859792868936858796788895
Consolidated Other Countries Revenue ($M)($M)
640679781798595701701624612621599469
Consolidated Total International Revenue ($M)($M)
7,1737,1097,2377,2306,8696,7977,2687,7168,0368,1077,3348,048
Geographic Long-Lived Assets — United States ($M)($M)
15,29115,09715,02115,48215,18214,89114,72413,915
Geographic Long-Lived Assets — EMEA ($M)($M)
9,0768,9668,8568,6658,5548,4027,5487,562
Geographic Long-Lived Assets — China ($M)($M)
210213218208204198202193
Geographic Long-Lived Assets — Japan ($M)($M)
129136144147144145143133
Geographic Long-Lived Assets — Asia Pacific ($M)($M)
8508428989489669739821,022
Geographic Long-Lived Assets — Latin America ($M)($M)
131128128139135135133222
Geographic Long-Lived Assets — Other Countries ($M)($M)
505151505149474
DB Income Statement — Consolidated Sales / Revenue ($M)($M)17
16,60716,28616,40017,27615,80615,52915,62416,65716,11215,77514,63015,962
Cost of Sales ($M)($M)
4,3954,1955,5513,8553,5573,4193,8284,0803,7453,5403,9124,264
Selling, General and Administrative (SG&A) ($M)($M)
2,9042,7002,8982,6332,6492,5522,8642,7312,7392,4832,8042,519
Research and Development (R&D) ($M)($M)
9,74112,5923,8864,2344,0483,6214,5845,8623,5003,9929,6273,307
Restructuring Costs ($M)($M)
1511952134756069515680123255126
Other (Income) Expense, Net ($M)($M)
-99-138-432238735-127162-4233-78-126
Interest Income ($M)($M)
353569966910914612769737073
Interest Expense ($M)($M)
525479411327305313328330310303310317
Gain (Loss) on Equity Investments ($M)($M)
242168-19537310090-155-3156143100-33
Income Before Taxes ($M)($M)
-683-3,5343,4206,7454,9995,9034,1704,0906,0065,670-2,0465,620
Taxes on Income ($M)($M)
654709458958571818426929545903-820870
Less: Net Income Attributable to Noncontrolling Interests ($M)($M)
-2-3-1216146505
Net Income Attributable to Merck & Co., Inc. ($M)($M)
-1,335-4,2402,9635,7854,4275,0793,7433,1575,4554,762-1,2264,745
Basic EPS ($)($)
-0.54-1.722.321.762.011.252.151.881.87
Diluted EPS ($)($)
-0.54-1.722.321.762.011.242.141.871.86
Weighted-Average Basic Shares (M)
2,470.002,472.002,495.002,510.002,523.002,534.002,534.002,533.002,537.00
Weighted-Average Diluted Shares (M)
2,470.002,472.002,498.002,513.002,531.002,541.002,544.002,544.002,546.00
Dividends Declared per Common Share ($)($)
0.850.850.850.810.810.810.810.770.770.770.770.73
DB Balance Sheet — Total Assets ($M)($M)27
129,802128,685136,866129,546117,523115,122117,106117,532112,630105,849106,675106,727
Cash and Cash Equivalents ($M)($M)
6,8495,32714,56518,1698,0738,73213,31814,68811,3735,6716,9098,669
Short-Term Investments ($M)($M)
29237504561559944705040252168
Accounts Receivable, Net ($M)($M)1
12,56412,21011,77512,12011,84610,79010,27811,38111,64211,36610,34910,394
Allowance for Doubtful Accounts ($M)($M)
10810397939493897982808885
Inventories ($M)($M)
6,2076,4796,6586,4446,6016,1966,1096,2446,4696,5106,3586,131
Other Current Assets ($M)($M)
10,76710,62410,51810,7799,9969,2898,7068,1438,7407,9508,3686,656
Total Current Assets ($M)($M)
36,67935,01543,51647,55737,06535,50338,78240,36138,20531,44532,16831,954
Property, Plant and Equipment (PP&E), Net ($M)($M)1
25,73725,43325,31625,63925,23624,79323,77923,44623,22123,04523,05122,526
PP&E — Less Allowance for Depreciation ($M)($M)
-22,729-22,288-21,914-20,605-20,256-19,680-19,155-19,072-18,960-18,620-18,266-18,446
Goodwill ($M)($M)
21,58221,58121,57921,58721,59121,68421,66821,69721,16121,18121,19721,183
Other Intangibles, Net ($M)($M)
24,97825,74526,68115,31315,19315,75816,37017,01016,98417,57218,01119,199
Long-Term Investments ($M)($M)
1,2221,1059561,1177746164635753572802521,306
Other Noncurrent Assets ($M)($M)
19,60419,80618,81818,33317,66416,76816,04414,44312,70212,32611,99610,559
Trade Accounts Payable ($M)($M)
3,8273,8634,4044,1473,8923,7844,0793,5863,5193,5143,9223,509
Loans Payable and Current Portion of Long-Term Debt ($M)($M)
2,8252,4442,5891,4051,4341,3602,6493,1493,0713,0771,372887
Income Taxes Payable ($M)($M)
4,2243,9464,7264,8484,1565,1813,9144,3302,7772,3982,6491,981
Accrued and Other Current Liabilities ($M)($M)
14,72514,54914,46816,18614,50212,77215,69416,53914,71214,10215,76614,840
Total Current Liabilities ($M)($M)
27,73126,94528,32728,62826,03725,17428,42029,58626,06025,09925,69423,094
Long-Term Debt ($M)($M)
51,08146,67346,75039,96933,96833,48434,46234,98234,71731,14233,68333,972
Deferred Income Taxes ($M)($M)
1,4331,4941,4391,3811,4271,4091,3878648769228711,018
Other Noncurrent Liabilities ($M)($M)
7,5737,6427,6887,6617,0316,6556,4657,5407,3298,2628,7927,343
Common Stock ($M)($M)
1,7881,7881,7881,7881,7881,7881,7881,7881,7881,7881,7881,788
Other Paid-In Capital ($M)($M)
44,95045,17645,02944,83244,64444,81644,70444,53044,36244,59844,50944,358
Retained Earnings ($M)($M)
63,26966,72173,07572,23168,47766,09763,06961,38460,18756,69753,89557,082
Accumulated Other Comprehensive Loss ($M)($M)
-3,942-4,060-4,287-5,202-5,421-4,965-4,945-5,371-5,361-5,274-5,161-4,916
Treasury Stock, at Cost ($M)($M)
-64,132-63,747-62,999-61,799-60,495-59,401-58,303-57,829-57,394-57,445-57,450-57,066
Merck & Co., Inc. Stockholders' Equity ($M)($M)
41,93345,87852,60651,85048,99348,33546,31344,50243,58240,36437,58141,246
Noncontrolling Interests ($M)($M)
515356576765595866605454
Total Equity ($M)($M)
41,98445,93152,66251,90749,06048,40046,37244,56043,64840,42437,63541,300
DB Cash Flow — Operating Cash Flow ($M)($M)14
5,3703,9182,8577,8223,2932,5003,4509,2915,6373,0902467,717
Capital Expenditures ($M)($M)
8939911,0339877641,328937783791861989902
Depreciation and Amortization ($M)($M)
5995811,448532518502518553518511474452
Stock-Based Compensation ($M)($M)
298185205204216195187195203176167164
Deferred Income Taxes ($M)($M)
-544-315-825-212-448-186-616-401-181-51-931-336
Acquisitions of Businesses, Net of Cash Acquired ($M)($M)
0-8,779-10,0420001,344-5980-74600
Purchases of Securities and Other Investments ($M)($M)
-148-37400-612-595-4550-49-15-251-117
Net Cash Used in Investing Activities ($M)($M)
-5,602-10,210-11,201-283-770-1,487-1,444-3,845-1,069-1,37653-334
Payments on Debt ($M)($M)
-5-1,140-2-10-2,500-53900-751-3-1
Dividends Paid to Stockholders ($M)($M)
-2,144-2,105-2,018-2,031-2,077-2,050-1,951-1,953-1,986-1,950-1,852-1,855
Purchases of Treasury Stock ($M)($M)
-757-874-1,252-1,323-1,345-1,164-489-444-251-122-393-466
Net Cash Used in Financing Activities ($M)($M)
1,762-2,9814,7512,638-3,556-5,755-3,009-2,4251,216-2,814-2,245-4,269
Effect of Exchange Rate Changes on Cash ($M)($M)
-37-192310374156-367294-82-138186-157
Net Increase (Decrease) in Cash and Cash Equivalents ($M)($M)
1,493-9,292-3,57010,187-659-4,586-1,3703,3155,702-1,238-1,7602,957
Cash Paid for Interest ($M)($M)
654342451233383233478241364217422229

109 metrics have no data in the last 12 quarters — .

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics
  • Fiscal calendar: Merck & Co., Inc. operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026). Merck reports two operating segments — Pharmaceutical and Animal Health — while commercial performance is driven by brand-level Worldwide / U.S. / International sales across Oncology, Vaccines, Cardiopulmonary & Hospital Acute Care, Virology, Diabetes, and Animal Health.
  • Core commercial, GTN & R&D KPIs (Groups 1–7) cover: (1) Oncology Portfolio (Keytruda $8,229M WW / $5,088M U.S. / $3,141M Intl in Q2 2026 and $31,680M in FY25; subcutaneous Keytruda Qlex $226M in Q2 2026; Welireg $228M in Q2 2026; Lynparza alliance $398M; Lenvima alliance $273M; Reblozyl royalty $164M; Koselugo alliance $62M); (2) Vaccines Portfolio ($22,554M Total Vaccines in FY25; Gardasil/Gardasil 9 $1,089M in Q2 2026 & China sales breakdown; ProQuad/M-M-R II/Varivax $652M in Q2 2026 with individual Varivax $400M, ProQuad $247M & M-M-R II $119M in Q2 2026 and Q4 = FY − 9M split; Vaxneuvance $262M; Capvaxive $207M; RotaTeq $157M; Pneumovax 23 $35M); (3) Cardiopulmonary, Respiratory & Hospital Acute Care (Winrevair $467M in Q2 2026 / $1,443M in FY25; Ohtuvayre $171M in Q2 2026 following the Verona Pharma acquisition; Adempas/Verquvo Bayer alliance $176M & direct Adempas $85M; Bridion $470M; Prevymis $268M; Dificid; Zerbaxa); (4) Diabetes, Virology & Immunology (Total Diabetes $2,442M in FY25 across Januvia & Janumet; Lagevrio; Isentress; Delstrigo; Pifeltro; Simponi; Remicade; Belsomra; plus pre-spin legacy brands); (5) Animal Health ($1,775M in Q2 2026 / $6,354M in FY25 across Livestock $1,009M and Companion Animal $766M, including Bravecto $396M in Q2 2026 / $1.2B in FY25) & 9-region Pharmaceutical Geographic Sales ($M and % share); (6) U.S. Gross-to-Net (GTN) Customer Discounts Rollforward ($3,907M ending accrual at FY25; $21,375M FY25 provision; $21,150M payments; $2,500M in Q2 2026), 6 Strategic Alliances (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback), and R&D Breakdown (MRL Direct $11.5B vs. Animal Health/BD/Support $6.4B in FY25); and (7) GAAP vs. Non-GAAP Reconciliation, Other (Income) Expense breakdown, and 2024 & 2019 Restructuring Programs.
  • Groups 8–11 cover: (8) Inventories by stage ($12,588M total net current & noncurrent at Q2 2026: Current $6,207M, Long-Term $5,900M, Pre-Launch, Finished Goods $2,186M, Raw Materials & WIP $11,194M, Supplies $309M, LIFO Reserve $1,101M), Drug-Specific Net Intangible Assets (Winrevair $9,424M, Bridion $1,949M, Adempas $203M at Q2 2026), Operating Leases, Defined Benefit Pension & OPEB Plans, and Income Tax / UTB Rollforward ($2,500M UTB at FY25); (9) Global Workforce (30,451 U.S. / 43,722 Non-U.S. employees, 8.5% overall / 5.4% voluntary turnover in FY25), Form 11-K across 3 employee benefit plans (Merck US Savings Plan $13,205M, Puerto Rico Savings Plan $155M, ESPP $376M net assets at FY25, plus Master Trust asset classes), Form SD 3TG Smelters (222 identified / 159 RMAP-conformant in FY25), and Merck Impact Report ESG metrics (48.6M people reached with social investments, 94.3% OTIF, Scope 1/2/3 GHG, energy, water, waste); (10) Spun-Off Subsidiary Self-Disclosed Data for Organon & Co. (NYSE: OGN, CIK 0001821825, spun off June 2, 2021 — P&L, balance sheet, geography, and 24 Women's Health, Biosimilar & Established Brands); and (11) FRED Pharmaceutical & Healthcare Macro Benchmarks and Postgres DB Segment & Financial Statement Context.
  • No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Not shown because recent periods are missing (15)

  • Mảng Thú y (Animal Health: Livestock, Companion Animal, Bravecto) & Địa lý Dược phẩm (Pharmaceutical Regions) › Animal Health Segment — Worldwide sales ($M) › Animal Health — Companion Animal (vaccines & parasiticides) — Worldwide sales ($M) › Bravecto (fluralaner parasiticides line) — Quarterly sales Q1–Q3 ($M; Q4 not separately disclosed) › Bravecto — Worldwide constant-currency (ex-exchange) growth YoY (%)
  • Mảng Thú y (Animal Health: Livestock, Companion Animal, Bravecto) & Địa lý Dược phẩm (Pharmaceutical Regions) › Pharmaceutical Segment — Worldwide sales ($M) › Pharmaceutical Segment — Total International sales ($M) › Pharmaceutical Segment — International reported growth YoY (%)
  • Chiết khấu Gross-to-Net (U.S. GTN Rollforward), Liên minh Hợp tác (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & Cơ cấu R&D › Collaboration — AstraZeneca (Lynparza & Koselugo Oncology Alliance) ($M) › AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Noncurrent liabilities to partner ($M)
  • Chiết khấu Gross-to-Net (U.S. GTN Rollforward), Liên minh Hợp tác (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & Cơ cấu R&D › Collaboration — Eisai Co., Ltd. (Lenvima Oncology Alliance) ($M) › Eisai Co., Ltd. (Lenvima Oncology Alliance) — Current payables / liabilities to partner ($M)
  • Chiết khấu Gross-to-Net (U.S. GTN Rollforward), Liên minh Hợp tác (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & Cơ cấu R&D › Collaboration — Eisai Co., Ltd. (Lenvima Oncology Alliance) ($M) › Eisai Co., Ltd. (Lenvima Oncology Alliance) — Noncurrent liabilities to partner ($M)
  • Chiết khấu Gross-to-Net (U.S. GTN Rollforward), Liên minh Hợp tác (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & Cơ cấu R&D › Collaboration — Eisai Co., Ltd. (Lenvima Oncology Alliance) ($M) › Eisai Co., Ltd. (Lenvima Oncology Alliance) — Intangible asset amortization in Cost of Sales ($M)
  • Chiết khấu Gross-to-Net (U.S. GTN Rollforward), Liên minh Hợp tác (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & Cơ cấu R&D › Collaboration — Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) ($M) › Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Noncurrent liabilities to partner ($M)
  • Chiết khấu Gross-to-Net (U.S. GTN Rollforward), Liên minh Hợp tác (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & Cơ cấu R&D › Collaboration — Daiichi Sankyo (3 DXd ADC Oncology Programs) ($M) › Daiichi Sankyo (3 DXd ADC Oncology Programs) — Noncurrent liabilities to partner ($M)
  • Chiết khấu Gross-to-Net (U.S. GTN Rollforward), Liên minh Hợp tác (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & Cơ cấu R&D › Collaboration — Ridgeback Biotherapeutics (Lagevrio Antiviral Alliance) ($M) › Ridgeback (Lagevrio) — R&D reimbursement from partner ($M)
  • Đối chiếu GAAP vs. Non-GAAP (Table 2a), Thu nhập/Chi phí Khác (Table 4) & Chương trình Tái cấu trúc (2024 & 2019 Programs) › Restructuring Programs — Total Period Charges Across All Programs ($M) › 2024 Restructuring Program (Supply Network & Commercial Optimization) — Total Period Charges Incurred ($M) › 2024 Restructuring Program (Supply Network & Commercial Optimization) — Recorded in SG&A ($M)
  • Đối chiếu GAAP vs. Non-GAAP (Table 2a), Thu nhập/Chi phí Khác (Table 4) & Chương trình Tái cấu trúc (2024 & 2019 Programs) › Restructuring Programs — Total Period Charges Across All Programs ($M) › 2024 Restructuring Program (Supply Network & Commercial Optimization) — Total Period Charges Incurred ($M) › 2024 Restructuring Program (Supply Network & Commercial Optimization) — Recorded in R&D ($M)
  • Đối chiếu GAAP vs. Non-GAAP (Table 2a), Thu nhập/Chi phí Khác (Table 4) & Chương trình Tái cấu trúc (2024 & 2019 Programs) › Restructuring Programs — Total Period Charges Across All Programs ($M) › 2019 Restructuring Program (legacy) — Total Period Charges Incurred ($M) › 2019 Restructuring Program (legacy) — Cumulative Charges Incurred Since Inception ($M)
  • Nguồn Ngoài Ngành Dược (FRED Benchmarks) & Bối cảnh Phân khúc / Tài chính từ DB (Segments & Financial Statements — Đặt Cuối Bảng) › DB Income Statement — Consolidated Sales / Revenue ($M) › Income from Continuing Operations ($M)
  • Nguồn Ngoài Ngành Dược (FRED Benchmarks) & Bối cảnh Phân khúc / Tài chính từ DB (Segments & Financial Statements — Đặt Cuối Bảng) › DB Cash Flow — Operating Cash Flow ($M) › Proceeds from Sales of Securities and Other Investments ($M)
  • Nguồn Ngoài Ngành Dược (FRED Benchmarks) & Bối cảnh Phân khúc / Tài chính từ DB (Segments & Financial Statements — Đặt Cuối Bảng) › DB Cash Flow — Operating Cash Flow ($M) › Net Change in Short-Term Borrowings ($M)

Data updated 2026-10-26.

Every KPI on its own page

Full history, chart, sources and a citation for each metric

Key Chính — Danh mục Ung thư (Oncology Portfolio: Keytruda, Keytruda Qlex, Welireg & Oncology Alliances)

Danh mục Vắc-xin (Vaccines Portfolio: Gardasil, Pediatric Vaccines, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23)

Tim-Phổi, Hô hấp & Chăm sóc Cấp cứu Bệnh viện (Winrevair, Ohtuvayre, Adempas/Verquvo, Bridion, Prevymis, Dificid, Zerbaxa)

Kháng Virus, Tiểu đường, Miễn dịch & Nhãn hiệu Lịch sử (Diabetes, Virology, Immunology & Pre-Organon Legacy Brands)

Mảng Thú y (Animal Health: Livestock, Companion Animal, Bravecto) & Địa lý Dược phẩm (Pharmaceutical Regions)

Chiết khấu Gross-to-Net (U.S. GTN Rollforward), Liên minh Hợp tác (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & Cơ cấu R&D

Đối chiếu GAAP vs. Non-GAAP (Table 2a), Thu nhập/Chi phí Khác (Table 4) & Chương trình Tái cấu trúc (2024 & 2019 Programs)

Hàng tồn kho theo Giai đoạn & Pre-Launch, Tài sản Vô hình theo Thuốc, Thuê hoạt động, Lương hưu & Thuế

Nhân sự Toàn cầu (DEF 14A), Quỹ Tiết kiệm Nhân viên (Form 11-K — 3 Quỹ & Master Trust), Khoáng sản Xung đột (Form SD) & Bền vững (Merck Impact Report)

Công ty Tách ra Tự công bố — Organon & Co. (NYSE: OGN, CIK 0001821825 — Women's Health, Biosimilars & Established Brands)

Nguồn Ngoài Ngành Dược (FRED Benchmarks) & Bối cảnh Phân khúc / Tài chính từ DB (Segments & Financial Statements — Đặt Cuối Bảng)